Nasdaq:US$17.54 (-0.39) | HKEX:HK$26.92 (-0.76) | AIM:£2.52 (+0.02)
搜索
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2014-06-03

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors